Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Ken Yasaka¹, Tomohide Yamazaki², Hiroko Sato¹, Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae⁴, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²SBI Biotech, Tokyo, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…
Abstract Number: 1711 • ACR Convergence 2022
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
Jie An, Xizhang Sun, Lena Tanaka and Keith Elkon, University of Washington, Seattle, WA
Background/Purpose: SLE patients characteristically have a type I interferon (IFN-I) signature in peripheral blood cells and this same signature is prominent in lesional and non-lesional…
Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi¹, Catherine Park², Sangeeta Sule² and Sun-Young Ahn², ¹Children's National Hospital, New York, NY, ²Children's National Hospital, Washington, DC
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
Abstract Number: 2063 • ACR Convergence 2022
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Alfredo Aguirre¹, Kimberly DeQuattro², Patricia Katz³, Kurt Greenlund⁴, Kamil Barbour⁴, Caroline Gordon⁵, Cristina M Lanata⁶, Lindsey Criswell⁷, Maria Dall'Era⁸ and Jinoos Yazdany⁹, ¹University of California, San Francisco, San Francisco, CA, ²University of Pennsylvania, Philadelphia, PA, ³UCSF, San Rafael, CA, ⁴Centers for Disease Control and Prevention, Atlanta, GA, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁶NIH/NHGRI, Washington, DC, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸University of California, Division of Rheumatology, San Francisco, CA, ⁹UCSF, San Francisco, CA
Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…
Abstract Number: 2081 • ACR Convergence 2022
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Amit Saxena¹, Alexis Engel², Brittany Banbury¹, Ghadeer Hasan³, Nicola Fraser¹, Devyn Zaminski¹, Mala Masson⁴, Rebecca Haberman⁵, Jose Scher², Gary Ho⁶, Jammie Law³, Paula Rackoff¹, Chung-E Tseng⁵, H Michael Belmont¹, Robert Clancy¹, Jill Buyon⁷ and Peter Izmirly⁷, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone, New York, NY, ⁴NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…
Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
Abstract Number: 2225 • ACR Convergence 2022
Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus
Sarah Patterson¹, Sebastian Cruz Gonzalez², Alexandra Tsitsiklis², Cristina Lanata³, Lenka Maliskova⁴, Chun Ye¹, Zachary Cutts⁴, Jinoos Yazdany⁵, Maria Dall'Era⁶, Lindsey Criswell⁷, Charles Langelier², Patricia Katz⁵ and Marina Sirota⁸, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³NIH, Washington, DC, ⁴University of California, San Francisco, San Francisco, ⁵UCSF, San Rafael, CA, ⁶University of California, Division of Rheumatology, San Francisco, CA, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸UCSF, SF
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L03 • ACR Convergence 2021
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
Abstract Number: L08 • ACR Convergence 2021
Association of Limited Health Literacy with Clinical and Patient-Reported Outcomes in Systemic Lupus Erythematosus: An Analysis from the Peer Approaches to Lupus Self-Management (PALS) Program
Mithu Maheswaranathan¹, Andrea Boan², Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose-Smith⁴, Clara Dismuke-Greer⁵, Leonard Egede⁶, Jim Oates² and Edith Williams², ¹Duke University, Durham, NC, ²Medical University of South Carolina, Charleston, SC, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, NY, ⁵VA Palo Alto, Palo Alto, CA, ⁶Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information. Limited HL is associated…
Abstract Number: L13 • ACR Convergence 2021
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Cynthia Aranow¹, Cornelia Allaart², Zahir Amoura³, Ian N Bruce⁴, Patricia Cagnoli⁵, Richard Furie¹, Paul Peter Tak⁶, Murray Urowitz⁷, Ronald van Vollenhoven⁸, Kenneth L Clark⁶, Mark Daniels⁹, Norma Lynn Fox¹⁰, Yun Irene Gregan¹⁰, James Groark¹¹, Robert B Henderson⁹, Mary Oldham⁹, Don Shanahan⁹, Andre van Maurik⁹, David A Roth¹⁰ and YK Onno Teng², ¹Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, ²Leiden University Medical Center, Leiden, Netherlands, ³Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, ⁴NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵University of Michigan Medical Center, Ann Arbor, MI, ⁶GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, ⁷Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁸Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹GlaxoSmithKline, Stevenage, United Kingdom, ¹⁰GlaxoSmithKline, Collegeville, PA, ¹¹GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
Abstract Number: 0006 • ACR Convergence 2021
Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells
Ivan Ramirez¹, Betty Diamond² and Sun Jung Kim³, ¹Northwell, Little Neck, NY, ²Northwell Health, Manhasset, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Since the description of age-associated B cells (ABC), there has been a growing interest in the role of these cells in autoimmunity. Evidence suggests…
Abstract Number: 0233 • ACR Convergence 2021
Feasibility and Acceptability of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Katherine Carpenter¹, Melissa French¹, Sara Balestrieri², Sara Johnson², Sarah Gilman³, Cristina Drenkard⁴, S Sam Lim⁵, Maria Dall'Era⁶, Emily Somers⁷, Suzanna Zick⁸, Victoria Werth⁹, Daniel Wallace¹⁰, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Pro-Change Behavior Systems, South Kingstown, RI, ³Wayfinder Health Strategies, Falls Church, VA, ⁴Emory University, Atlanta, GA, ⁵Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶University of California San Francisco, Corte Madera, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸Department of Family Medicine and Nutritional Sciences, Ann Arbor, MI, ⁹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁰Cedars-Sinai, Los Angeles, CA
Background/Purpose: The Lupus Foundation of America (LFA) has completed a 5-year cooperative agreement with the CDC to develop and evaluate an online lupus self-management (SM)…
Abstract Number: 0337 • ACR Convergence 2021
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Ben Boone and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Infection is the leading cause of mortality and one of the most common causes of hospitalization in patients with systemic lupus erythematosus (SLE). Pneumocystis…
Abstract Number: 0456 • ACR Convergence 2021
Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus
John Hanly¹, Jason Robertson¹, Lyna Kamintsky¹, Alon Friedman¹, Steven Beyea¹, John Fisk¹, Antonina Omisade¹, Cindy Calkin¹, Tim Bardouille¹, Chris Bowen¹, Alexandra Legge¹, Arnold Mitnitski², Kara Matheson² and Javeria Hashmi¹, ¹Dalhousie University, Halifax, NS, Canada, ²Nova Scotia Health Authority, Halifax, NS, Canada
Background/Purpose: Cognitive impairment is the most frequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), yet the mechanisms underlying it remain poorly understood. We have previously…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].